TWP
VRTX icon

TFO Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

TFO Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2
Closed -$836 – 727
2024
Q1 		$836 Hold
2
– – ﹤0.01% 188
2023
Q4 		$814 Sell
2
-5
-71% -$1.85K ﹤0.01% 235
2023
Q3 		$2.46K Buy
7
+5
+250% +$1.75K ﹤0.01% 194
2023
Q2 		$704 Hold
2
– – ﹤0.01% 236
2023
Q1 		$630 Buy
2
+1
+100% +$300 ﹤0.01% 215
2022
Q4 		$14 Buy
+1
New +$305 ﹤0.01% 916
2022
Q3 		– Sell
-19
Closed -$5K – 490
2022
Q2 		$5K Buy
+19
New +$5.08K ﹤0.01% 218

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TFO Wealth Partners's VRTX Position: Q2 2024 in Review

TFO Wealth Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 2 shares — an estimated $836 sold.

TFO Wealth Partners first reported a position in VRTX in Q2 2022 and held it in 7 quarters. The position peaked at $5K in Q2 2022. 1,549 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • TFO Wealth Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • TFO Wealth Partners sold 2 Vertex Pharmaceuticals shares in Q2 2024, an estimated $836.
  • TFO Wealth Partners first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 7 quarters.
  • TFO Wealth Partners's Vertex Pharmaceuticals position peaked at $5K in Q2 2022.
  • 1,549 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on TFO Wealth Partners's 13F filing for Q2 2024, filed 15 Aug 2024.